Oregon Health & Science University, U.S.
New findings in diabetes described from the United States
Published in Physician Law Weekly, October 11th, 2006
Study 1: Sulfonylurea therapy may be compromised by K+ channel expression in Kir6.2 variants of neonatal diabetes.
"Heterozygous missense mutations in the pore-forming subunit Kir6.2 of ATP-sensitive K+ channels (KATP channels) have recently been shown to cause permanent neonatal diabetes mellitus (PNDM). Functional studies demonstrated that PNDM mutations reduce KATP , channel sensitivity to ATP inhibition, resulting in gain of channel function. However, the impact of these mutations on channel expression has not been examined,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2006-10-11)
More Articles from Physician Law Weekly
- Aastrom Biosciences
Aastrom Biosciences reports on clinical trial status, fundraising - AngioDynamics
AngioDynamics comments on judgment decision by court - Barr Pharmaceuticals
Barr files an amended tender offer for Pliva - Forensic Psychology Practice , U.K.
Treatment of sexual offenders with learning disabilities in the community is focus of review - Identa
Drug detection products made by IDenta earn acceptance of Chinese Federal Police - Indiana University, U.S.
Bioethics program in predictive health is established at Indiana University - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
